Novel in vivo TDP-43 stress reporter models to accelerate drug development in ALS.
Ferro, F.; Wolf, C. R.; Henstridge, C. M.; Inesta-Vaquera, F.
Show abstract
The development of therapies to combat neurodegenerative diseases is widely recognised as a research priority, with conditions like Alzheimers, Amyotrophic lateral sclerosis (ALS) and Parkinsons set to place an ever-heavier burden on healthcare systems in the near future. Despite recent advances in understanding their molecular basis, there is a lack of suitable early biomarkers to test selected compounds and accelerate their translation to clinical trials. We have investigated the utility of in vivo reporters of cytoprotective pathways (e.g. NRF2, p53) as surrogate early biomarkers of the ALS degenerative disease progression. We hypothesized that cellular stress observed in a model of ALS may precede overt cellular damage and could activate our cytoprotective pathway reporters. To test this hypothesis, we generated novel ALS-reporter mice by crossing the hTDP-43tg model into our oxidative stress/inflammation (Hmox1; NRF2 pathway) and DNA damage (p21; p53 pathway) stress reporter models. Histological analysis of reporter expression in a homozygous hTDP-43tg background demonstrated a time-dependent and tissue-specific activation of the reporters in tissues directly associated with ALS. The activation occurs in Purkinje neurons and other parvalbumin-positive (PV+) cells within the cerebellum of mice, before moderate clinical signs are observed. In addition, reporter expression in hTDP-43tg hom peripheral tissues was not observed at the tested mouse ages (15 and 17 days postnatally). Further work is warranted to determine the specific mechanisms by which TDP-43 accumulation leads to reporter activation and whether therapeutic intervention modulates reporters expression. Our current studies suggest that these reporters may represent a powerful approach to accelerate preclinical studies targeting TDP-43 pathologies. We anticipate the reporter strategy could be of great value in developing treatments for a range of degenerative disorders.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Voluntary running does not increase capillary blood flow but promotes neurogenesis and short-term memory in the APP/PS1 mouse model of Alzheimers disease 93%
- Age-related changes in Tau and Autophagy in human brain in the absence of neurodegeneration 93%
- Queuine, a bacterial derived hypermodified nucleobase, shows protection in in vitro models of neurodegeneration 93%
Similar papers in this journal
- Triac treatment prevents neurodevelopmental and locomotor impairments in thyroid hormone transporter Mct8/Oatp1c1 deficient mice 96%
- Neuronal Dot1l is a broad mitochondrial gene-repressor associated with human brain aging via H3K79 hypermethylation 94%
- Alterations in leptin signaling in Amyotrophic Lateral Sclerosis (ALS) 94%
Similar papers in this journal
- Genetic dissection of Down syndrome-associated alterations in APP/amyloid-β biology using mouse models 94%
- Neuroimmune characterization of optineurin insufficiency mouse model during ageing 94%
- Behavioral, neural and ultrastructural alterations in a graded-dose 6-OHDA mouse model of early-stage Parkinson's disease 94%
Similar papers in this journal
Similar papers in this journal
- Spinocerebellar Ataxia Type 1 protein Ataxin-1 is signalled to DNA damage by Ataxia Telangiectasia Mutated kinase 94%
- MCOLN1 gene-replacement therapy corrects neurologic dysfunction in the mouse model of mucolipidosis IV. 94%
- The GBA variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines. 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.